Skip to Content

Xeloda (capecitabine) Disease Interactions

There are 6 disease interactions with Xeloda (capecitabine):


Antineoplastics (Includes Xeloda) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.


  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  4. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  5. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  6. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  7. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  8. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  9. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  10. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  11. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  12. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  13. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  14. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  16. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  17. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  18. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  19. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  20. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  21. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  22. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  23. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  24. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  26. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  27. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  28. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  29. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  30. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  31. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
View all 31 references

Capecitabine (Includes Xeloda) ↔ Coronary Artery Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Ischemic Heart Disease

Capecitabine can cause cardiotoxicity including myocardial infarction, ischemia, angina, dysrhythmias, cardiac failure, sudden death, electrocardiographic changes and cardiomyopathy. These adverse reactions can be more common in patients with a prior history of coronary artery disease.


Capecitabine (Includes Xeloda) ↔ Myelosuppression

Severe Potential Hazard, Moderate plausibility

Applies to: Fever, Bleeding, Bone Marrow Depression/Low Blood Counts

Capecitabine is metabolized by the liver to fluorouracil (5-FU). Fluorouracil induces bone marrow suppression. Leukopenia, thrombocytopenia, and anemia, some severe, have been reported with capecitabine therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended


  1. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.

Capecitabine (Includes Xeloda) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min). Patients with moderate renal impairment at baseline require a dose reduction. Patients with mild and moderate impairment should be carefully monitored for adverse reactions and prompt interruption of therapy with subsequent dose adjustment might be required depending on the developed adverse events.


Capecitabine (Includes Xeloda) ↔ Dehydration

Moderate Potential Hazard, Moderate plausibility

Applies to: Dehydration, Diarrhea, Vomiting

Dehydration has been observed in patients receiving capecitabine and it may cause acute renal failure which could be fatal. Patients with asthenia, anorexia, nausea, vomiting or diarrhea may rapidly become dehydrated. Patients should be monitored to prevent and correct dehydration at the onset. If dehydration grade 2 or higher occurs, treatment should be interrupted until dehydration is corrected. Since capecitabine can also induce diarrhea, sometimes severe, patients should be carefully monitored and receive fluid and electrolyte replacement. Standard antidiarrheal treatments are recommended.


Capecitabine (Includes Xeloda) ↔ Hepatic Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Capecitabine is extensively metabolized by the liver. In patients with mild to moderate liver dysfunction due to liver metastases the Cmax and AUC of capecitabine were increased 60%. These patients should be carefully monitored when capecitabine is administered. The effect of severe hepatic dysfunction on capecitabine has not been assessed. Clinical monitoring of hepatic function is recommended for patients with compromised hepatic function.


  1. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.

Xeloda (capecitabine) drug Interactions

There are 280 drug interactions with Xeloda (capecitabine)

Xeloda (capecitabine) alcohol/food Interactions

There is 1 alcohol/food interaction with Xeloda (capecitabine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.